ADAM17-dependent Autocrine and Paracrine Signaling Promotes Pancreatic Premalignant Progression
KRAS<sup>G12D</sup>-driven tumorigenesis requires both autocrine and paracrine signaling regulated by ADAM17. Beyond activating EGFR to drive acinar cell transdifferentiation, ADAM17 also promotes neoplastic progression by modulating additional pro-tumor signaling that shapes the fibroinflammatory microenvironment. These findings highlight a pivotal role for ADAM17 in orchestrating epithelial plasticity, cellular signaling, and stromal remodeling during pancreatic tumorigenesis.
Authors
- Nina G. Steele (ORCID: https://orcid.org/0000-0003-1564-3562)
- Simone Benitz (ORCID: https://orcid.org/0009-0005-9019-9176)
- Elaine M. Hurt (ORCID: https://orcid.org/0009-0005-3801-9537)
- Daniel James Salas-Escabillas (ORCID: https://orcid.org/0000-0002-0819-989X)
- Jacee Moore (ORCID: https://orcid.org/0009-0007-3853-7769)
- Howard C. Crawford (ORCID: https://orcid.org/0000-0001-9360-3019)
- Erick T. Davis
- Ian M. Loveless (ORCID: https://orcid.org/0000-0003-4645-6559)
- Brian S. Devorkin
- Hui‐Ju Wen (ORCID: https://orcid.org/0000-0003-1268-3120)
- Sydney Brender
- Holly McQuithey
- Allison M. Wombwell
- Justin Lee (ORCID: https://orcid.org/0000-0002-3657-4386)
- Daniel W. Long
Institutions
- Ford Motor Company (United States) (US)
- Michigan Department of Health and Human Services (US)
- Henry Ford Health System (US)
- AstraZeneca (Finland) (FI)
- University of Cincinnati Medical Center (US)
Publication Details
- Journal
- Cellular and Molecular Gastroenterology and Hepatology
- Published
- 2025-12-20
- DOI
- https://doi.org/10.1016/j.jcmgh.2025.101711
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00